AU2001245319A1 - Methods of treating diseases with activated protein c - Google Patents

Methods of treating diseases with activated protein c

Info

Publication number
AU2001245319A1
AU2001245319A1 AU2001245319A AU4531901A AU2001245319A1 AU 2001245319 A1 AU2001245319 A1 AU 2001245319A1 AU 2001245319 A AU2001245319 A AU 2001245319A AU 4531901 A AU4531901 A AU 4531901A AU 2001245319 A1 AU2001245319 A1 AU 2001245319A1
Authority
AU
Australia
Prior art keywords
activated protein
methods
treating diseases
disease
pathological condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245319A
Other languages
English (en)
Inventor
Angelina Vucic Ciaccia
Lawrence Mark Gelbert
Brian William Grinnell
Bryan Edward Jones
David Eugene Joyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001245319A1 publication Critical patent/AU2001245319A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
AU2001245319A 2000-03-28 2001-03-21 Methods of treating diseases with activated protein c Abandoned AU2001245319A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19275500P 2000-03-28 2000-03-28
US60192755 2000-03-28
PCT/US2001/005823 WO2001072328A2 (en) 2000-03-28 2001-03-21 Methods of treating diseases with activated protein c

Publications (1)

Publication Number Publication Date
AU2001245319A1 true AU2001245319A1 (en) 2001-10-08

Family

ID=22710924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245319A Abandoned AU2001245319A1 (en) 2000-03-28 2001-03-21 Methods of treating diseases with activated protein c

Country Status (9)

Country Link
EP (1) EP1267915B1 (pt)
JP (1) JP2003528153A (pt)
AT (1) ATE298246T1 (pt)
AU (1) AU2001245319A1 (pt)
CA (1) CA2404231A1 (pt)
DE (1) DE60111620T2 (pt)
ES (1) ES2242740T3 (pt)
PT (1) PT1267915E (pt)
WO (1) WO2001072328A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108076T2 (de) 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
ES2384099T3 (es) 2001-06-13 2012-06-29 The University Of Sydney Proteína C para cicatrización de heridas
DE10158561A1 (de) * 2001-11-29 2003-06-12 Bayer Ag Neue Verwendung von Cyclopentabenzofuranen
CA2508276C (en) * 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
KR101284884B1 (ko) * 2003-07-08 2013-07-10 더 스크립스 리서치 인스티튜트 정상의 세포보호 활성 및 저하된 항응고 활성을 지닌활성화 단백질 c 변이체
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
RU2595857C2 (ru) * 2012-05-31 2016-08-27 Кинки Юниверсити Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством
IN2014DN11181A (pt) 2012-07-04 2015-10-02 Univ Sydney
US20170042982A1 (en) * 2014-04-16 2017-02-16 Zz Biotech Llc Treatment of abnormal cutaneous scarring
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP4256497B2 (ja) * 1998-08-06 2009-04-22 旭化成ファーマ株式会社 血管炎治療剤
JP2000219633A (ja) * 1999-01-29 2000-08-08 Chemo Sero Therapeut Res Inst 虚血性腎障害の予防・治療剤

Also Published As

Publication number Publication date
PT1267915E (pt) 2005-09-30
EP1267915B1 (en) 2005-06-22
DE60111620T2 (de) 2006-05-18
ATE298246T1 (de) 2005-07-15
CA2404231A1 (en) 2001-10-04
ES2242740T3 (es) 2005-11-16
EP1267915A2 (en) 2003-01-02
WO2001072328A3 (en) 2002-02-14
DE60111620D1 (de) 2005-07-28
JP2003528153A (ja) 2003-09-24
WO2001072328A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
PT1567667E (pt) Tratamento da doença de huntington com epa
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
AU2003243096A1 (en) NOVEL PURINE- OR PYRROLOL(2,3-d)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY
WO2000043781A3 (en) Growth differentiation factor inhibitors and uses therefor
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
AU2001245319A1 (en) Methods of treating diseases with activated protein c
AU7408301A (en) Novel target genes for diseases of the heart
AU6090799A (en) Transgenic c. elegans as a model organism for research into alzheimer's disease
DE60015508D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
MXPA02001204A (es) Compuestos calciliticos.
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU2003237493A1 (en) Methods for treating diseases or conditions with peptide constructs
WO2003027229A3 (en) Antisense modulation of rip2 expression
EP1344536A4 (en) METHOD FOR REGULATING THE ACTIVITY OF EXPRESSION OF A GENETIC PRODUCT TRANSFERRED INTO A LIVING ORGANISM
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
WO2002038803A3 (de) Neue marker für die diagnose und therapie von tumoren
PT1064265E (pt) Sintese de 3-amino-2-cloro-4-metilpiridina a partir de malononitrilo e acetona
ZA200407358B (en) Microorganism for genetic therapeutic treatment ofproliferative diseases.
WO2004048531A3 (en) Modulation of death-associated protein kinase 1 expression
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
EP1211931A4 (en) "KNOCKOUT" MOUSE FOR THE ANX7 TUMOR SUPPRESSOR ORGAN